Jun 15, 2022 / 06:20PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Thanks so much for joining us. Really pleased to have the Gilead team here with us. We have Dan O'Day, CEO; and Merdad Parsey, CMO.
With that, Dan, I'll turn it over to you for any opening comments, and then we can jump into Q&A.
Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO
Sure, sure. Well, first of all, thanks for coming here and being with us today. I'm delighted to be here with Merdad. Look, I think this is an exciting time at Gilead for us right now. We are coming off of also, I think, a strong ASCO in terms of the entirety of data that we have. I would just say that -- and we'll get into the questions. But I think what the team at Gilead has built up over the past couple of years has really been impressive, and what I mean by that is the pipeline has increased by more than 50%.
That number, I think, really underestimates what the potential of the pipeline is because the whole nature of the pipeline has changed accordingly. Our
Gilead Sciences Inc at Goldman Sachs Global Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers